Treatment for severe liver inflammation in children
Treatments studied
Part of Digestive system clinical trials.
This trial tests a drug called emapalumab (given by IV) to calm the immune system in children and young adults with very severe liver inflammation that hasn't improved with standard treatment. The goal is to see if it can help the liver recover and avoid the need for a transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The person must be at least 1 year old.
- A blood test must show very high liver enzymes (ALT of 1000 or more) within the last week.
- For the treatment group, the liver inflammation must have not improved with steroids, or come back after stopping them, and doctors have not found a known cause.
- The person must not have liver failure, chronic liver disease, or signs of confusion from liver problems.
- The person must not have active infections like hepatitis A, B, C, HIV, or a severe respiratory infection needing breathing support.
- The person must not have cancer, kidney failure, or be on a ventilator, and must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, mycophenolate mofetil and prednisone, to treat moderate to severe liver inflammation caused by immunotherapy. The goal is to see if this treatment can help control the inflammation without needing long-term high-dose steroids.
This trial studies a way to treat inflammation of the liver (hepatitis) caused by immune cancer medicines (anti-PD-1/PD-L1, sometimes with anti-CTLA-4) without relying on high-dose steroids. It may help reduce steroid side effects while keeping liver inflammation under control.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial tests whether using low-dose steroids can safely manage liver inflammation caused by immunotherapy. It may help patients who have moderate liver problems from their cancer treatment but haven't yet started high-dose steroids.
This study tests a new biologic medicine called inebilizumab that may help people whose autoimmune hepatitis hasn't improved with standard treatments. The goal is to see if it can reduce liver inflammation and improve their condition.
This study follows people who develop liver inflammation (hepatitis) after starting immunotherapy for cancer. It helps doctors understand how often this happens and how to manage it.
Hear when a new Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.